Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2015 1
2019 5
2020 3
2021 5
2022 3
2023 20
2024 23
2025 43
2026 23

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

113 results

Results by year

Citations

5 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
Did you mean eplizumab type 1 diabetes delay (3,953 results)?
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group. Herold KC, et al. N Engl J Med. 2019 Aug 15;381(7):603-613. doi: 10.1056/NEJMoa1902226. Epub 2019 Jun 9. N Engl J Med. 2019. PMID: 31180194 Free PMC article. Clinical Trial.
Some interventions have delayed the loss of insulin production in patients with type 1 diabetes, but interventions that might affect clinical progression before diagnosis are needed. ...CONCLUSIONS: Teplizumab delayed progression to clini …
Some interventions have delayed the loss of insulin production in patients with type 1 diabetes, but interventio …
ISPAD Clinical Practice Consensus Guidelines 2024: Screening, Staging, and Strategies to Preserve Beta-Cell Function in Children and Adolescents with Type 1 Diabetes.
Haller MJ, Bell KJ, Besser REJ, Casteels K, Couper JJ, Craig ME, Elding Larsson H, Jacobsen L, Lange K, Oron T, Sims EK, Speake C, Tosur M, Ulivi F, Ziegler AG, Wherrett DK, Marcovecchio ML. Haller MJ, et al. Horm Res Paediatr. 2024;97(6):529-545. doi: 10.1159/000543035. Epub 2024 Dec 11. Horm Res Paediatr. 2024. PMID: 39662065 Free PMC article. Review.
This guideline serves as an update to the 2022 ISPAD consensus guideline on staging for type 1 diabetes (T1D). Key additions include an evidence-based summary of recommendations for screening for risk of T1D and monitoring those with early-stage T1D. ...This …
This guideline serves as an update to the 2022 ISPAD consensus guideline on staging for type 1 diabetes (T1D). Key addi …
Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective.
Sims EK, Besser REJ, Dayan C, Geno Rasmussen C, Greenbaum C, Griffin KJ, Hagopian W, Knip M, Long AE, Martin F, Mathieu C, Rewers M, Steck AK, Wentworth JM, Rich SS, Kordonouri O, Ziegler AG, Herold KC; NIDDK Type 1 Diabetes TrialNet Study Group. Sims EK, et al. Diabetes. 2022 Apr 1;71(4):610-623. doi: 10.2337/dbi20-0054. Diabetes. 2022. PMID: 35316839 Free PMC article. Review.
Most screening programs to identify individuals at risk for type 1 diabetes have targeted relatives of people living with the disease to improve yield and feasibility. However, 90% of those who develop type 1 diabetes do not have a famil …
Most screening programs to identify individuals at risk for type 1 diabetes have targeted relatives of people living wi …
The Changing Epidemiology of Type 1 Diabetes: A Global Perspective.
Bell KJ, Lain SJ. Bell KJ, et al. Diabetes Obes Metab. 2025 Aug;27 Suppl 6(Suppl 6):3-14. doi: 10.1111/dom.16501. Epub 2025 Jun 19. Diabetes Obes Metab. 2025. PMID: 40536127 Free PMC article. Review.
The prevalence of type 1 diabetes is increasing, with significant implications for public health systems worldwide. This review provides a global overview of the current epidemiology of type 1 diabetes, examining the trends, risk factors, …
The prevalence of type 1 diabetes is increasing, with significant implications for public health systems worldwide. Thi …
Teplizumab and beta-Cell Function in Newly Diagnosed Type 1 Diabetes.
Ramos EL, Dayan CM, Chatenoud L, Sumnik Z, Simmons KM, Szypowska A, Gitelman SE, Knecht LA, Niemoeller E, Tian W, Herold KC; PROTECT Study Investigators. Ramos EL, et al. N Engl J Med. 2023 Dec 7;389(23):2151-2161. doi: 10.1056/NEJMoa2308743. Epub 2023 Oct 18. N Engl J Med. 2023. PMID: 37861217 Clinical Trial.
BACKGROUND: Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to delay the onset of clinical type 1 diabetes (stage 3) in patients 8 years of age or older with preclinical (stage 2) di …
BACKGROUND: Teplizumab, a humanized monoclonal antibody to CD3 on T cells, is approved by the Food and Drug Administration to dela …
Teplizumab in Type 1 Diabetes Mellitus: An Updated Review.
Thakkar S, Chopra A, Nagendra L, Kalra S, Bhattacharya S. Thakkar S, et al. touchREV Endocrinol. 2023 Nov;19(2):22-30. doi: 10.17925/EE.2023.19.2.7. Epub 2023 Oct 6. touchREV Endocrinol. 2023. PMID: 38187075 Free PMC article. Review.
Type 1 diabetes mellitus (T1DM) is a chronic autoimmune condition characterized by the irreversible destruction of the beta cells of the pancreas, which leads to a lifelong dependency on exogenous insulin. ...In November 2022, teplizumab became …
Type 1 diabetes mellitus (T1DM) is a chronic autoimmune condition characterized by the irreversible destruction …
The future of type 1 diabetes therapy.
Ziegler AG, Cengiz E, Kay TWH. Ziegler AG, et al. Lancet. 2025 Oct 4;406(10511):1520-1534. doi: 10.1016/S0140-6736(25)01438-2. Epub 2025 Sep 19. Lancet. 2025. PMID: 40983070 Free article. Review.
The treatment of type 1 diabetes is entering a transformative era. Teplizumab, the first immunotherapy treatment to delay the onset of clinical type 1 diabetes, has been approved by the US Food and Drug Administration. ...To …
The treatment of type 1 diabetes is entering a transformative era. Teplizumab, the first immunotherapy treatment …
Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves beta-Cell Function.
Herold KC, Gitelman SE, Gottlieb PA, Knecht LA, Raymond R, Ramos EL. Herold KC, et al. Diabetes Care. 2023 Oct 1;46(10):1848-1856. doi: 10.2337/dc23-0675. Diabetes Care. 2023. PMID: 37607392 Free PMC article.
OBJECTIVE: In November 2022, teplizumab-mzwv became the first drug approved to delay the onset of stage 3 type 1 diabetes in adults and children age 8 years with stage 2 type 1 diabetes on the basis of data from the pivotal …
OBJECTIVE: In November 2022, teplizumab-mzwv became the first drug approved to delay the onset of stage 3 type 1 …
Teplizumab Therapy to Delay the Onset of Type 1 Diabetes.
Novograd J, Frishman WH. Novograd J, et al. Cardiol Rev. 2024 Nov-Dec 01;32(6):572-576. doi: 10.1097/CRD.0000000000000563. Epub 2023 May 9. Cardiol Rev. 2024. PMID: 37158990 Review.
Type 1 diabetes mellitus (T1DM) is an autoimmune disease that results in the destruction of insulin-producing pancreatic beta cells. ...This article provides an overview of the discovery and mechanism of action of teplizumab, as well as the clin …
Type 1 diabetes mellitus (T1DM) is an autoimmune disease that results in the destruction of insulin-producing pa …
Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetes.
Lledó-Delgado A, Preston-Hurlburt P, Currie S, Clark P, Linsley PS, Long SA, Liu C, Koroleva G, Martins AJ, Tsang JS, Herold KC. Lledó-Delgado A, et al. J Clin Invest. 2024 Aug 13;134(18):e177492. doi: 10.1172/JCI177492. J Clin Invest. 2024. PMID: 39137044 Free PMC article. Clinical Trial.
BACKGROUNDTeplizumab, a non-FcR-binding anti-CD3 mAb, is approved to delay progression of type 1 diabetes (T1D) in at-risk patients. Previous investigations described the immediate effects of the 14-day treatment, but longer-term effects of the drug re …
BACKGROUNDTeplizumab, a non-FcR-binding anti-CD3 mAb, is approved to delay progression of type 1 diabetes (T1D) …
113 results